Hyperhomocysteinemia and thrombosis: The search for a link

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 6, Issue 3, 1996, Pages 168-177

  Mancini, F P ^a   Di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Homocysteine; Thrombosis

Indexed keywords

EID: 0001366244     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Ueland PM, Refsum H (1989) Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 114: 473-501
2. Malinow MR, Kang SS, Taylor LM, Wong PWK, Inahara T, Mukerjee D (1989) Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation 79: 1180-1188
3. Mudd SH, Levy HL (1989) Disorders in transsulfuration. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 693-734
4. Kang SS, Wong PWK, Bock HG, Horwitz A, Grix A (1991) Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutation. Am J Hum Genet 48: 456-461
5. Stabler SP, Marcell PD, Podell ER, Allen RH (1987) Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 162: 185-196
6. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW (1983) Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 72: 1971-1976
7. Kang SS, Wong PWK, Cook HY, Norusis M, Messler JV (1986) Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest 77: 1482-1486
8. Brattström L, Israelsson B, Jeppsson J-O (1986) Heterozygosity for homocystinuria in premature arterial disease. New Engl J Med 314: 849-850
9. McCully KS (1969) Vascular pathology of homocysteinemia implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128
10. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 274: 1049-1057
11. Carson NAJ, Neill DW (1962) Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 37: 505-513
12. Mudd SH, Skovby F, Levy HL, Pettigrew RD, Wilcken B, Pyeritz RE, Andria G, et al (1985) The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 37: 1-31
13. Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE (1972) Homocystinuria associated with decreased methylenete-trahydrofolate reductase activity. Biochem Biophys Res Commun 46: 905-912
14. Cooper BA, Rosenblat DS (1987) Inherited defects of vitamin B12 metabolism. Annu Rev Nutr 7: 291-320
15. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Shaefer EJ, Malinow MR (1990) Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 16: 1114-1119
16. Taylor LM, DeFrang RD, Harris EJ, Porter JM (1991) The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13: 128-136
17. Olszewski AJ, Szostak WB (1988) Homocysteine content of plasma proteins in ischemic heart disease. Atherosclerosis 69: 109-113
18. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, et al (1995) Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332: 286-291
19. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM (1994) High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14: 1080-1083
20. Fermo I, Viganò D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A (1995) Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 123: 747-753
21. Finkelstein JD, Mudd SH, Irreverre F, Laster L (1964) Homocystinuria due to cystathionine synthase deficiency: the mode of inheritance. Science 146: 785-787
22. Ueland PM, Refsum H, Brattström L (1992) Plasma homocysteine and cardiovascular disease. In: Francis RB, Jr (ed) Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. Marcel Dekker, Inc, New York, Basel, Hong Kong, pp 183-236
23. Clarke R (1990) The Irish experience. In: Robinson K (ed) Homocysteinaemia and vascular disease, Luxembourg: Commission of the European Communities, pp 41-48
24. Rubba P, Faccenda F, Pauciullo P, Carbone L, Mancini M, Strisciuglio P, Carrozzo R, et al (1990) Early signs of vascular disease in homocystinuria: a noninvasive study by ultrasound methods in eight families with cystathionine-β-synthase deficiency. Metabolism 39: 1191-1195
25. Rubba P, Mercuri M, Faccenda F, Iannuzzi A, Irace C, Strisciuglio P, Gnasso A, et al (1994) Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke 25: 943-950
26. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 10: 111-113
27. de Franchis R, Mancini FP, D' Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, et al (1996) Elevated total plasma homocysteine and 677C→T mutation of the 5,10-methylenete-trahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 59: 262-264
28. Malinow MR (1994) Homocyst(e)ine and arterial occlusive disease. J Intern Med 236: 603-617
29. Brattström LE, Hultberg BL, Hardebo JE (1985) Folic acid responsive postmenopausal homocysteinemia. Metabolism 34: 1073-1077
30. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81: 466-474
31. Wilcken DEL, Gupta VJ, Betts AK (1981) Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 61: 743-749
32. Wilcken DEL, Dudman NPB, Tyrrel PA, Robertson MR (1988) Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 37: 697-701
33. Wilcken DEL, Reddy SG, Gupta VJ (1983) Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 32: 363-370
34. Brattström LE, Israelson B, Jeppsson J-O, Hultberg BL (1988) Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48: 215-221
35. Chauveau P, Chadefaux B, Coudè M, Aupetit J, Kamoun P, Jungers P (1996) Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 22: 106-109
36. Harker LA, Slichter SJ, Scott RC, Ross R (1974) Homocysteinemia. Vascular injury and arterial thrombosis. N Engl J Med 291: 537-543
37. Harker LA, Ross R, Slichter SJ, Scott CR (1976) Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58: 731-741
38. Harker LA, Scott RC (1977) Platelets in homocystinuria. N Engl J Med 296: 818
39. De Groot PG, Willems C, Boers GHJ, Gonsalves MD, Van Haken WG, Van Mourik JA (1983) Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 13: 405-410
40. Blann AD (1992) Endothelial cell damage and homocysteine. Atherosclerosis 94: 89-91
41. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh C-M, Haber E, Schlegel R, Lee M-E (1994) Promotion of vascular smooth muscle cells growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91: 6369-6373
42. Wall RT, Harlan JM, Harker LA, Striker JE (1980) Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18: 113-121
43. Dudman NPB, Hicks C, Wang J, Wilcken DEL (1991) Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 91: 77-83
44. Starkebaum G, Harlan JM (1986) Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77: 1370-1376
45. Zwart J, Van Wolput HMC, Van der Cammen JCM, Konigsberger DC (1981) Accumulation and reactions of hydrogen peroxide during the copper ion catalyzed auto oxidation of cysteine in alkaline medium. J Mol Catal 11: 69-82
46. Warso MA, Lands WEM (1985) Presence of lipid hydroperoxide in human plasma. J Clin Invest 75: 667-671
47. Taylor L, Menconi MJ, Polgar P (1983) The participation of hydroperoxides and oxygen radicals in the control of prostaglandin synthesis. J Biol Chem 258: 6855-6857
48. Whorton AR, Montgomery ME, Kent RS (1985) Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. J Clin Invest 76: 295-302
49. Heinecke JW, Rosen H, Chait A (1984) Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 74: 1890-1894
50. Panganamala RV, Karpen CW, Merola AJ (1986) Peroxide-mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukot Med 22: 349-356
51. Graeber JE, Slott JH, Ulane R, Schulman JD, Stuart JJ (1982) Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 16: 490-493
52. Wang J, Dudman NPB, Wilcken DEL (1993) Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 70: 1047-1052
53. Giannini MJ, Coleman M, Innerfield I (1975) Antithrombin activity in homocystinuria. J Clin Pathol 1: 1094
54. Maruyama I, Fukuda R, Kazama M (1977) A case of homocystinuria with low antithrombin activity. Acta Haematol Jpn 40: 267-271
55. Palareti G, Salardi S, Piazzi S, Legnani C, Poggi M, Grauso F, Caniato A, et al (1986) Blood coagulation changes in homocystinuria: effects of pyroxidine and other specific therapy. J Pediatr 109: 1001-1006
56. Charlot JC, Haye C, Chaumien JP (1982) Homocystinuric et deficit en facteur VII. Bull Soc Ophthalmol Fr, pp 787-789
57. Mercky J, Kuntz F (1981) Deficit en facteur VII et homocystinnurie. Association fortuite ou syndrome? Nouv Presse Med 10: 3796
58. Rodgers GM, Kane WH (1986) Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator. J Clin Invest 77: 1909-1916
59. Rodgers GM, Conn MT (1990) Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 75: 895-901
60. Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914
61. Parkinson JF, Grinnell BW, Moore RE, Hoskins J, Vlahos C, Bang NU (1990) Stable expression of a secretable deletion mutant of recombinant human soluble thrombomodulin in mammalian cells. J Biol Chem 265: 12602-12610
62. Hayashi T, Honda G, Suzuki K (1992) An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 79: 2930-2936
63. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM (1993) Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13: 1327-1333
64. Nishinaga M, Ozawa T, Shimada K (1993) Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92: 1381-1386
65. Hajjar KA (1993) Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91: 2873-2879
66. Harpel PC, Chang VT, Borth W (1992) Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193-10197
67. McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G, Scanu A, et al (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330: 132-137
68. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF (1989) A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339: 301-303
69. Hajjar KA, Gavish D, Breslow JL, Nachman RL (1989) Lipoprotein(a) modulates endothelial cell fibrinolysis: potential role in atherosclerosis. Nature 339: 303-305
70. Hill-Zobel RL, Pyeritz RE, Scheffel U, Malpica O, Engin S, Camarge EE, Abbott M, et al (1982) Kinetics and distribution of "Indium-labeled" platelets in patients with homocystinuria due to cystathionine synthase deficiency. N Engl J Med 307: 781-786
71. McDonald L, Bray C, Field C, Love F, Davies B (1964) Homocystinuria, thrombosis, and the blood-platelets. The Lancet :i: 745-746
72. Schimke RN, McKusick VA, Hwang T, Pollack AD (1965) Homocystinuria. Studies of 20 families with 38 affected members. J Am Med Assoc 193: 711
73. McCully KS, Carvalho ACA (1987) Homocysteine thiolactone. N-homocysteine thiolactonyl retinamide and platelet aggregation. Res Commun Chem Pathol Pharmacol 56: 349-360
74. Davis JW, Flournoy LD, Phillips PE (1975) Amino acids and collagen-induced platelet aggregation. Am J Dis Child 129: 1020-1021
75. Zweifler AJ, Allen RJ (1971) An intrinsic platelet abnormality in a homocystinuric boy corrected by pyridoxine administration. Thromb Diath Haemorr XXVI: 15-21
76. Hilden M, Brandt NJ, Nilsson IM, Schonheyder F (1974) Investigation of coagulation and fibrinolysis in homocystinuria. Acta Med Scand 195
77. Jocelyn PC (1972) Biochemistry of the SH group. Academic Press, Ltd., London, pp 39 and 253
78. Randon J, Lecompte T, Chignard M, Siess W, Marlas G, Dray F, Vargaftig BB (1981) Dissociation of platelet activation from transmethylation of their membrane phospholipids. Nature 293: 660-662
79. Stamler JS, Osborne JA, Jaraki M, Rabbini LE, Mullins M. Singel D, et al (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91: 308-318
80. Thomas G, Skrinska VA, Lucas FV (1986) The influence of glutathione and other thiols on human platelet aggregation. Thromb Res 44: 859-866
81. Vesterqvist O, Gréen K (1984) Urinary excretion of 2,3-dinorthromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 27: 627-644
82. Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, et al (1993) Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 92: 1400-1406
83. Witzum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792
84. Parthasarathy S, Young SG, Witzum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoproteins. J Clin Invest 77: 641-644
85. Parthasarathy S (1987) Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochem Biophys Acta 917: 337-340
86. Misra HP (1974) Generation of superoxide free radicals during the autoxidation of thiols. J Biol Chem 249: 2151-2155
87. Saez G, Thornalley PJ, Hill HAO, Hems R, Bannister JV (1982) The production of free radicals during autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta 719: 24-31